1. Home
  2. CETX vs BLRX Comparison

CETX vs BLRX Comparison

Compare CETX & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cemtrex Inc.

CETX

Cemtrex Inc.

HOLD

Current Price

$1.13

Market Cap

12.3M

Sector

Technology

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$2.91

Market Cap

12.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CETX
BLRX
Founded
1998
2003
Country
United States
Israel
Employees
244
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
12.6M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
CETX
BLRX
Price
$1.13
$2.91
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$19.00
AVG Volume (30 Days)
6.2M
17.4K
Earning Date
05-12-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$20.41
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.37
$2.15
52 Week High
$9.70
$7.77

Technical Indicators

Market Signals
Indicator
CETX
BLRX
Relative Strength Index (RSI) 52.98 66.53
Support Level $0.56 $2.66
Resistance Level $1.41 $3.11
Average True Range (ATR) 0.10 0.20
MACD -0.01 0.09
Stochastic Oscillator 19.70 75.30

Price Performance

Historical Comparison
CETX
BLRX

About CETX Cemtrex Inc.

Cemtrex Inc is a multi-industry technology company. It has expanded into a range of sectors, including smart technologies, virtual and augmented realities, industrial solutions, and intelligent security systems. The company's operating segment includes the Security segment and the Industrial Services segment. The security segment provides end-to-end security to all industrial, corporate, and governmental security via its owned subsidiary, Vicon. Whereas the AIS part Industrial Service Segment is expertise services for rigging, millwrighting, in-plant maintenance, equipment erection, relocation, and disassembly to diversified customers. It generates maximum revenue from the Industrial Service Segment, and from the USA. It also operates UK, USA, and Other.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: